
Opinion|Videos|August 5, 2024
Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response
Key opinion leaders explore molecular characteristics beyond mutations that influence immunotherapy response in non small cell lung cancer treatment.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Beyond genomic mutations like STK11/KEAP1/KRAS, are there other molecular characteristics that can influence immunotherapy effectiveness and should guide treatment selection?
Advertisement
Related to this article

FDA approves dexmedetomidine sublingual film for at-home use in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.

Once weekly ribupatide, a dual GIP/GLP-1 receptor agonist, led to significantly greater weight loss than placebo at 48 weeks, according to a study.

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.

A TriNetX retrospective cohort found adults with alopecia areata—especially women—face a nearly doubled glaucoma risk, with implications for ophthalmology and comorbidities.

β3 agonists were not linked to lower dementia incidence vs anticholinergics among 830,393 adults treated for overactive bladder, a cohort study found.

Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.
Advertisement
Advertisement
Trending on AJMC
1
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
2
FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy
3
FDA Approves Weekly Gefurulimab for Generalized Myasthenia Gravis
4
No Surprises Act Arbitration Added $8.39B in 2025 Plan Obligations
5

